Two Sigma Advisers’s Fulcrum Therapeutics FULC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $565K | Sell |
82,100
-195,700
| -70% | -$1.35M | ﹤0.01% | 1696 |
|
|
2025
Q1 | $800K | Sell |
277,800
-65,800
| -19% | -$190K | ﹤0.01% | 1571 |
|
|
2024
Q4 | $1.61M | Sell |
343,600
-38,600
| -10% | -$181K | ﹤0.01% | 1221 |
|
|
2024
Q3 | $1.36M | Sell |
382,200
-181,300
| -32% | -$647K | ﹤0.01% | 1268 |
|
|
2024
Q2 | $3.49M | Buy |
563,500
+143,300
| +34% | +$888K | 0.01% | 921 |
|
|
2024
Q1 | $3.97M | Sell |
420,200
-76,000
| -15% | -$717K | 0.01% | 871 |
|
|
2023
Q4 | $3.35M | Sell |
496,200
-25,800
| -5% | -$174K | 0.01% | 1011 |
|
|
2023
Q3 | $2.32M | Sell |
522,000
-73,300
| -12% | -$325K | 0.01% | 1116 |
|
|
2023
Q2 | $1.96M | Buy |
595,300
+332,700
| +127% | +$1.1M | 0.01% | 1209 |
|
|
2023
Q1 | $748K | Buy |
262,600
+198,600
| +310% | +$566K | ﹤0.01% | 1771 |
|
|
2022
Q4 | $466K | Buy |
64,000
+13,700
| +27% | +$99.7K | ﹤0.01% | 1906 |
|
|
2022
Q3 | $407K | Sell |
50,300
-61,000
| -55% | -$494K | ﹤0.01% | 1933 |
|
|
2022
Q2 | $545K | Buy |
111,300
+25,800
| +30% | +$126K | ﹤0.01% | 1875 |
|
|
2022
Q1 | $2.02M | Sell |
85,500
-293,600
| -77% | -$6.94M | 0.01% | 1247 |
|
|
2021
Q4 | $6.71M | Buy |
379,100
+236,900
| +167% | +$4.19M | 0.02% | 645 |
|
|
2021
Q3 | $4.01M | Buy |
+142,200
| New | +$4.01M | 0.01% | 897 |
|